标题
Pharmacoeconomics of synthetic therapies for multiple sclerosis
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-10
出版商
Informa UK Limited
发表日期
2019-05-15
DOI
10.1080/14656566.2019.1615880
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A new way to estimate neurologic disease prevalence in the United States
- (2019) Lorene M. Nelson et al. NEUROLOGY
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women
- (2018) Nils Koch-Henriksen et al. NEUROLOGY
- Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis
- (2018) Alexander Rae-Grant et al. NEUROLOGY
- Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations
- (2018) Luis Hernandez et al. PHARMACOECONOMICS
- Induction or escalation therapy for patients with multiple sclerosis?
- (2018) E. Le Page et al. REVUE NEUROLOGIQUE
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England
- (2018) Robert Hettle et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands
- (2018) M. A. Piena et al. JOURNAL OF MEDICAL ECONOMICS
- The evolution of “No Evidence of Disease Activity” in multiple sclerosis
- (2018) G. Lu et al. Multiple Sclerosis and Related Disorders
- Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
- (2018) Marita Zimmermann et al. CNS DRUGS
- Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia
- (2018) Yen Hoang Le Phan et al. Multiple Sclerosis and Related Disorders
- Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
- (2017) GJ Melendez-Torres et al. HEALTH TECHNOLOGY ASSESSMENT
- Multiple sclerosis: Frequency, cost, and economic burden in the United States
- (2017) Alex Y. Chen et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
- (2017) Tomas Kalincik et al. LANCET NEUROLOGY
- New insights into the burden and costs of multiple sclerosis in Europe
- (2017) Gisela Kobelt et al. Multiple Sclerosis Journal
- Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis
- (2017) David Bargiela et al. NEUROLOGY
- Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies
- (2017) Sergio Iannazzo et al. PHARMACOECONOMICS
- New insights into the burden and costs of multiple sclerosis in Europe
- (2017) Gisela Kobelt et al. Multiple Sclerosis Journal
- Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis
- (2017) Hongbo Yang et al. JOURNAL OF MEDICAL ECONOMICS
- Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States
- (2016) Aseel Bin Sawad et al. CURRENT MEDICAL RESEARCH AND OPINION
- Can new chemical therapies improve the management of multiple sclerosis in children?
- (2016) Emanuele D’Amico et al. EXPERT OPINION ON PHARMACOTHERAPY
- Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study
- (2016) Emanuele D’Amico et al. JOURNAL OF NEUROLOGY
- US health insurance is an obstacle to disease-modifying treatments in MS
- (2016) Dennis Bourdette et al. NEUROLOGY
- Health insurance affects the use of disease-modifying therapy in multiple sclerosis
- (2016) Guoqiao Wang et al. NEUROLOGY
- Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis
- (2016) Luis Hernandez et al. JOURNAL OF MEDICAL ECONOMICS
- The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada
- (2016) Wenqing Su et al. JOURNAL OF MEDICAL ECONOMICS
- Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis
- (2016) Emer Fogarty et al. Multiple Sclerosis and Related Disorders
- Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective
- (2016) Julie Chevalier et al. PLoS One
- Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory
- (2016) C. Solaro et al. PLoS One
- Cost of Illness of Multiple Sclerosis - A Systematic Review
- (2016) Olivia Ernstsson et al. PLoS One
- Classification, diagnosis, and differential diagnosis of multiple sclerosis
- (2015) Ilana Katz Sand CURRENT OPINION IN NEUROLOGY
- Progressive multiple sclerosis
- (2015) Daniel Ontaneda et al. CURRENT OPINION IN NEUROLOGY
- Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal
- (2015) Emanuele D’Amico et al. Expert Review of Neurotherapeutics
- Cost of disease-modifying therapies for multiple sclerosis
- (2015) M. G. Brown NEUROLOGY
- The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
- (2015) D. M. Hartung et al. NEUROLOGY
- Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
- (2015) Livio Garattini et al. PHARMACOECONOMICS
- Estimating a Preference-Based Index for an Eight-Dimensional Health State Classification System for Multiple Sclerosis
- (2015) Elizabeth Goodwin et al. VALUE IN HEALTH
- Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom
- (2015) Felicity Allen et al. VALUE IN HEALTH
- Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal
- (2015) Emanuele D’Amico et al. Expert Review of Neurotherapeutics
- Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis
- (2015) Dennis Bourdette et al. JAMA Neurology
- Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
- (2015) Alberto Gajofatto et al. World Journal of Clinical Cases
- An initial validation of the Italian Mishel Uncertainty Illness Scale (MUIS) for relapsing remitting multiple sclerosis patients
- (2014) Maria Daniela Giammanco et al. NEUROLOGICAL SCIENCES
- Defining the clinical course of multiple sclerosis: The 2013 revisions
- (2014) F. D. Lublin et al. NEUROLOGY
- Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches
- (2014) Shien Guo et al. PHARMACOECONOMICS
- Epidemiology and clinical record of multiple sclerosis in selected countries: a systematic review
- (2013) Natalia Niedziela et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Measuring the Global Burden of Disease
- (2013) Christopher J.L. Murray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis
- (2013) Joel P. Thompson et al. PHARMACOECONOMICS
- Using existing data to identify candidate items for a health state classification system in multiple sclerosis
- (2013) Ayse Kuspinar et al. QUALITY OF LIFE RESEARCH
- Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
- (2013) Florian Castrop et al. Neuropsychiatric Disease and Treatment
- Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis
- (2013) Annie Hawton et al. Applied Health Economics and Health Policy
- Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States
- (2012) Feng Pan et al. CLINICAL THERAPEUTICS
- Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis
- (2012) Ali Manouchehrinia et al. Current Neurology and Neuroscience Reports
- Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy
- (2012) Korinna Karampampa et al. Multiple Sclerosis Journal
- Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries
- (2012) Korinna Karampampa et al. Multiple Sclerosis Journal
- Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis
- (2012) Stephanie R. Earnshaw et al. Applied Health Economics and Health Policy
- Potential Health Care Cost Savings Associated With Early Treatment of Multiple Sclerosis Using Disease-Modifying Therapy
- (2011) Suellen M. Curkendall et al. CLINICAL THERAPEUTICS
- Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica
- (2011) C. Tortorella et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Multiple sclerosis in Italy: cost-of-illness study
- (2011) F. Patti et al. NEUROLOGICAL SCIENCES
- The economic burden of Medicare-eligible patients by multiple sclerosis type
- (2011) Daniel M. Gilden et al. VALUE IN HEALTH
- Health outcomes in economic evaluation: the QALY and utilities
- (2010) S. J. Whitehead et al. BRITISH MEDICAL BULLETIN
- The changing demographic pattern of multiple sclerosis epidemiology
- (2010) Nils Koch-Henriksen et al. LANCET NEUROLOGY
- New perspectives in the natural history of multiple sclerosis
- (2010) H. Tremlett et al. NEUROLOGY
- Economic Burden of Multiple Sclerosis
- (2010) Huseyin Naci et al. PHARMACOECONOMICS
- Cost-effectiveness of four immunomodulatory therapies for relapsingremitting multiple sclerosis: A Markov model based on data a Balkan country in socioeconomic transition
- (2010) Slobodan Jankovic et al. Vojnosanitetski Pregled
- Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs
- (2009) Howard G. Birnbaum et al. CURRENT MEDICAL RESEARCH AND OPINION
- Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b
- (2009) Carlo Lazzaro et al. NEUROLOGICAL SCIENCES
- Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
- (2009) Ray Gani et al. PHARMACOECONOMICS
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now